List of Excipients in Branded Drug NEVIRAPINE

Generic Drugs Containing NEVIRAPINE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	nevirapine	0378-4050	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	nevirapine	0378-4050	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	nevirapine	0378-4050	MICROCRYSTALLINE CELLULOSE 101
Mylan Pharmaceuticals Inc	nevirapine	0378-4050	MICROCRYSTALLINE CELLULOSE 102
Mylan Pharmaceuticals Inc	nevirapine	0378-4050	POVIDONE K30
Mylan Pharmaceuticals Inc	nevirapine	0378-4050	SILICON DIOXIDE
Mylan Pharmaceuticals Inc	nevirapine	0378-4050	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in NEVIRAPINE?

# Of NDCs	Excipient
1	CARBOMER HOMOPOLYMER TYPE A
1	CARBOMER HOMOPOLYMER TYPE B
11	CELLULOSE, MICROCRYSTALLINE
2	COLLOIDAL SILICON DIOXIDE
3	CROSCARMELLOSE SODIUM
4	FERRIC OXIDE YELLOW
2	HYPROMELLOSE

Last updated: September 24, 2026

Nevirapine is a mature, low-cost antiretroviral with limited originator exclusivity and substantial generic competition. The strongest commercial opportunities are not in basic immediate-release tablets. They are in pediatric taste-masked products, dispersible and multiparticulate dosage forms, fixed-dose combinations, heat- and humidity-stable formulations, and differentiated delivery systems for markets with constrained manufacturing capacity. Excipient selection should address poor aqueous solubility, bitterness, dose flexibility, chemical stability, and low-cost scale-up.

Nevirapine Excipient Strategy, Formulation Patents, and Commercial Opportunities

What is the current commercial position of nevirapine?

Nevirapine is a non-nucleoside reverse transcriptase inhibitor used with other antiretroviral agents for HIV-1 infection. It was commercialized by Boehringer Ingelheim under the Viramune brand and is now available from multiple generic manufacturers.

The product has limited commercial momentum in high-income markets because newer regimens based on integrase inhibitors have displaced nevirapine in many treatment guidelines. Nevirapine remains relevant in lower-income and resource-constrained markets because of its low active pharmaceutical ingredient cost, established manufacturing base, pediatric use history, and inclusion in legacy antiretroviral procurement programs.

Attribute	Nevirapine
Active ingredient	Nevirapine
Drug class	Non-nucleoside reverse transcriptase inhibitor
Original brand	Viramune
Originator	Boehringer Ingelheim
Common strengths	200 mg immediate-release; 400 mg extended-release
Pediatric form	Oral suspension; dispersible products in selected markets
Typical role	Combination HIV therapy
Dosage form opportunity	Tablets, dispersible tablets, oral liquids, multiparticulates, fixed-dose combinations
Current competitive status	Mature generic market
Biosimilar exposure	None; nevirapine is a small molecule
Primary commercial constraint	Clinical displacement by newer antiretroviral regimens

The World Health Organization has progressively shifted preferred HIV treatment toward dolutegravir-based regimens because of stronger efficacy, resistance characteristics, and tolerability profiles. Nevirapine therefore has greater opportunity in access markets, pediatric supply, treatment-experienced populations, and markets where procurement economics outweigh premium clinical differentiation.[1]

What physicochemical properties determine the nevirapine excipient strategy?

Nevirapine is a weakly basic, poorly water-soluble molecule. Its limited intrinsic solubility creates formulation risk, particularly for liquid products, rapid-release tablets, low-dose pediatric presentations, and fixed-dose combinations.

Key formulation attributes include:

• Low aqueous solubility at neutral pH.
• pH-dependent dissolution.
• Moderate lipophilicity.
• Bitter taste that can limit pediatric adherence.
• High dose relative to many pediatric excipients and taste-masking systems.
• Need for chemical and physical stability under heat and humidity.
• Potential interaction between dissolution enhancers and the performance of combination products.

Nevirapine formulations should be designed around the target product profile rather than excipient availability alone. A low-cost adult tablet may require only a conventional filler, binder, disintegrant, lubricant, and film coat. A pediatric product requires a different architecture: rapid dispersion, acceptable taste, dose uniformity at small volumes, and stable performance after opening.

Which excipients are most suitable for immediate-release nevirapine tablets?

For conventional immediate-release tablets, the preferred strategy is a robust direct-compression or dry-granulation platform that minimizes manufacturing complexity.

Formulation function	Candidate excipients	Commercial rationale
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol	Supports tablet mass, flow, and cost control
Binder	Povidone, copovidone, pregelatinized starch, low-substituted hydroxypropyl cellulose	Controls granule strength and tablet hardness
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Accelerates tablet breakup and dissolution
Wetting agent	Sodium lauryl sulfate, poloxamers, surfactant blends	Improves contact between drug particles and dissolution medium
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports compression and ejection
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or approved colorants	Improves swallowability, identification, and moisture protection

Microcrystalline cellulose and crospovidone are commercially attractive because they support scalable tablet manufacture without requiring advanced processing. Sodium stearyl fumarate can be considered where magnesium stearate is associated with dissolution slowing, although its cost and regional availability may be less favorable.

Surfactants should be used conservatively. Sodium lauryl sulfate can improve wetting but may increase variability if its concentration is not tightly controlled. Excessive surfactant may affect tablet strength, taste, gastrointestinal tolerability, or the dissolution behavior of co-formulated antiretrovirals.

A practical first-line platform is:

1. Microcrystalline cellulose or partially pregelatinized starch as the primary diluent.
2. Crospovidone or croscarmellose sodium as the disintegrant.
3. Low-level povidone or copovidone as the binder.
4. Colloidal silicon dioxide for flow.
5. Magnesium stearate or sodium stearyl fumarate at a controlled concentration.
6. A moisture-barrier film coat where distribution occurs in hot and humid climates.

What excipients improve nevirapine dissolution?

Dissolution enhancement can be achieved through particle-size reduction, wetting, solid dispersion, or lipid-based systems. The best commercial choice depends on the product’s price target and regulatory burden.

Particle-size reduction

Micronized nevirapine can improve dissolution by increasing surface area. This approach is relatively simple and compatible with conventional tablets, but it may increase powder cohesion, electrostatic charging, segregation, and inhalation-control requirements during manufacturing.

The approach is most suitable when:

• The active ingredient can be milled without unacceptable polymorphic or amorphous changes.
• The target product is an immediate-release tablet.
• The manufacturer wants to avoid a complex new drug-delivery platform.
• The product must retain a low cost of goods.

Amorphous solid dispersions

Polymers such as hypromellose, hypromellose acetate succinate, polyvinylpyrrolidone, and copovidone can improve apparent solubility by maintaining nevirapine in a higher-energy amorphous state.

The main risks are:

• Recrystallization during storage.
• Moisture sensitivity.
• Process complexity.
• Need for solid-state characterization.
• More demanding stability packages.
• Potentially higher manufacturing cost.

Amorphous systems are more defensible from an intellectual-property perspective than standard tablets, but they require evidence of physical stability and bioequivalence.

Lipid and surfactant systems

Self-emulsifying or lipid-based systems can increase wetting and solubilization. They are more attractive for liquid-filled capsules, softgels, or specialized pediatric products than for low-cost high-volume tablets.

Potential excipients include medium-chain triglycerides, polyethylene glycol glycerides, polysorbates, poloxamers, and polyethylene glycol. The approach faces practical limitations in antiretroviral products because excipient taste, gastrointestinal tolerability, packaging compatibility, and pediatric acceptability can outweigh the dissolution benefit.

What excipients are best for pediatric nevirapine products?

Pediatric formulation is the clearest excipient-led commercial opportunity. The main product requirements are taste masking, flexible dosing, rapid dispersion, and stability after opening.

Oral suspension

Nevirapine oral suspension requires:

• A wetting system.
• Suspending agents such as xanthan gum, sodium carboxymethylcellulose, microcrystalline cellulose with carboxymethylcellulose sodium, or magnesium aluminum silicate.
• A buffer system compatible with drug stability.
• A preservative system where permitted and necessary.
• A sweetener and flavor system.
• A robust redispersibility profile.
• Packaging that supports accurate dosing.

Sucrose can provide effective taste masking but increases sugar exposure and may complicate use in some patient populations. Sorbitol, maltitol, sucralose, acesulfame potassium, and other intense sweeteners offer alternatives, although each affects mouthfeel and residual bitterness differently.

A suspension should be evaluated for sedimentation volume, redispersibility, dose uniformity throughout container use, microbial quality, viscosity, preservative effectiveness, and stability after repeated opening.

Dispersible tablets

Dispersible tablets can lower shipping and storage costs compared with ready-to-use liquids. A useful platform combines mannitol or lactose for mouthfeel, crospovidone or croscarmellose sodium for rapid breakup, and a taste-masking system.

Taste-masking options include:

• Polymer coating of drug particles.
• Ion-exchange resins.
• Lipid or wax barriers.
• Complexation with cyclodextrins.
• pH-modifying excipient systems.
• Multiparticulate coating.

Ion-exchange resins and polymer-coated particles can reduce direct contact between nevirapine and taste receptors. The tradeoff is that coating must release the drug rapidly after swallowing or dispersion. Excessive coating can slow dissolution and create bioequivalence risk.

Multiparticulates and granules

Multiparticulate granules can separate taste masking from dose flexibility. A product can be supplied as sachets, sprinkle granules, or capsules that are opened and dispersed in soft food or liquid.

This strategy is commercially attractive for:

• Infants and young children.
• Caregivers who need flexible dosing.
• Decentralized or community-based treatment.
• Programs that require low transport volume.
• Products intended to reduce liquid-spillage risk.

The formulation must control segregation, dose uniformity, moisture uptake, and the risk that caregivers chew coated particles and expose the bitter drug.

What formulation patents could protect a differentiated nevirapine product?

The original nevirapine compound and early product protections have expired or no longer create a material barrier to routine generic entry in major markets. Current protection, where available, is more likely to arise from formulation, manufacturing, combination, or method-of-use claims than from the active ingredient itself.

Potential patentable subject matter includes:

IP category	Possible claim focus	Commercial value
Taste masking	Coated nevirapine particles, resin complexes, lipid barriers	High for pediatric products
Solid dispersion	Specific polymer, ratio, process, and dissolution profile	Moderate to high
Dispersible tablet	Rapid dispersion, low friability, taste performance	Moderate
Oral suspension	Particle-size distribution, suspension system, preservative package	Moderate
Fixed-dose combination	Excipient compatibility and release profile for multiple actives	High where clinical use remains
Manufacturing	Low-solvent granulation, continuous processing, controlled particle engineering	Moderate
Stability	Moisture-protective packaging and formulation architecture	Moderate
Method of use	Specific pediatric or treatment-switching populations	Limited unless clinically differentiated

A formulation patent is stronger when it links composition to measurable performance, such as dissolution, taste threshold, redispersibility, stability, or bioavailability. Broad claims covering a routine mixture of nevirapine with common tablet excipients are vulnerable to obviousness and lack-of-inventive-step challenges.

What is the Orange Book and FDA regulatory status of nevirapine?

Nevirapine was approved in the United States as Viramune for use in combination with other antiretroviral agents. The immediate-release product received FDA approval in the 1990s, and an extended-release formulation was later approved as Viramune XR.[2]

The product is regulated as a small-molecule drug, not a biologic. Accordingly:

• Biosimilar pathways do not apply.
• Abbreviated New Drug Application pathways are relevant for generic products.
• Bioequivalence and dissolution remain central regulatory requirements.
• Formulation changes may require comparative pharmacokinetic data.
• Oral suspensions require controls for dose uniformity, microbial quality, and preservative performance.
• Fixed-dose combinations require evidence that the combination does not compromise the exposure or safety of the individual components.

The FDA Orange Book historically identified reference listed drugs and patent or exclusivity information for approved nevirapine products. The principal commercial significance of those protections has diminished because nevirapine is a mature generic active ingredient. Current product-specific Orange Book entries and patent listings must be checked against the live FDA database before a launch or freedom-to-operate decision.[3]

When did nevirapine lose exclusivity, and what generic entry risks exist?

Nevirapine no longer has meaningful compound-level exclusivity in the United States. Generic entry has occurred across immediate-release tablets, oral suspension, and other presentations in multiple jurisdictions.

The remaining entry risks are commercial and technical rather than basic compound-patent risks:

1. Failure to match dissolution or bioequivalence.
2. Pediatric palatability failure.
3. Inadequate stability in high-temperature or high-humidity zones.
4. Incompatibility in fixed-dose combinations.
5. Insufficient dose uniformity in suspensions or multiparticulates.
6. Manufacturing cost that exceeds tender-market pricing.
7. Regulatory difficulty supporting an extended-release or novel delivery system.
8. Procurement displacement by dolutegravir-based products.

Paragraph IV litigation is unlikely to be a central barrier for a conventional nevirapine generic because the major originator protections are historical. A Paragraph IV strategy could become relevant if a new formulation patent covers a differentiated product, particularly a pediatric delivery system, extended-release dosage form, or fixed-dose combination.

Which companies and products compete with nevirapine?

Nevirapine competes at two levels: against other nevirapine manufacturers in generic procurement and against alternative antiretroviral regimens in clinical practice.

Direct competition

Direct competitors include generic manufacturers supplying:

• 200 mg immediate-release tablets.
• Oral suspension.
• Extended-release tablets where approved.
• Combination products containing nevirapine with nucleoside reverse transcriptase inhibitors.

Manufacturers with established antiretroviral portfolios and access to Global Fund, PEPFAR, or other procurement channels have an advantage. Prequalification, quality-system maturity, and reliable supply can matter more than minor formulation differentiation.

Therapeutic competition

The main therapeutic competitors are dolutegravir-based regimens, boosted protease inhibitor regimens, efavirenz-based regimens, and newer fixed-dose combinations. Dolutegravir has become the dominant comparator in many treatment guidelines and procurement programs.[1]

Nevirapine retains commercial relevance where:

• Product price is highly constrained.
• Existing protocols or supply chains support nevirapine.
• Pediatric formulations are needed.
• Patients cannot use preferred alternatives.
• Local manufacturing or tender eligibility favors established products.

What licensing deals and access programs affect nevirapine?

Nevirapine has participated in the broader access and donation history of HIV medicines, including programs associated with prevention of mother-to-child transmission and pediatric treatment. Its commercial model is now primarily generic and procurement-driven rather than dependent on a current originator licensing strategy.

The most relevant business relationships are:

• Generic supply agreements.
• Public-sector tenders.
• Technology-transfer arrangements.
• Contract manufacturing.
• Regional registration partnerships.
• Voluntary quality-assurance or prequalification programs.

A new entrant can create value by combining formulation know-how with access to regulated-market filings, regional registrations, or public-procurement channels. A formulation patent alone is unlikely to support premium pricing unless it solves a visible clinical or supply-chain problem.

How strong is the nevirapine patent estate?

The compound-level estate is weak for new market entry because nevirapine is an old active ingredient with broad generic availability. A new product can still create a narrower but commercially useful estate around:

• Pediatric taste masking.
• Extended release.
• Improved stability.
• Novel fixed-dose combinations.
• Manufacturing processes that reduce cost or solvent use.
• Device-compatible delivery.
• Defined particle engineering.
• Specific excipient ratios linked to performance.

Patent strength depends on claim scope, prior-art density, measurable advantages, and freedom from existing formulation patents. A composition patent based only on familiar excipients is likely to be less durable than a product supported by pharmacokinetic, palatability, stability, or manufacturing data.

What commercial opportunities exist for nevirapine formulations?

The most attractive opportunities rank as follows:

Opportunity	Market rationale	Development risk	Commercial attractiveness
Taste-masked pediatric granules	Addresses adherence and dosing flexibility	Medium	High
Dispersible pediatric tablets	Reduces liquid logistics and improves portability	Medium	High
Heat-stable oral suspension	Supports tropical distribution	Low to medium	Moderate
Low-cost fixed-dose combination	Aligns with procurement requirements	Medium	Moderate to high
Amorphous solid dispersion	Improves dissolution and may support IP	High	Moderate
Extended-release product	Reduces dosing frequency	High	Limited to moderate
Novel lipid formulation	May improve solubilization	High	Limited
Standard adult immediate-release tablet	Mature, crowded market	Low	Low

The strongest near-term strategy is a pediatric, taste-masked, dispersible or multiparticulate product with demonstrated stability and competitive manufacturing economics. The formulation should be compatible with water, soft food, or a small dosing volume and should avoid cold-chain dependence.

What regulatory and manufacturing barriers affect commercialization?

The product should be developed for the intended regulatory pathway from the beginning. Standard tablets may rely on comparative dissolution and bioequivalence. Pediatric formulations may require additional evidence concerning dose uniformity, in-use stability, palatability, and administration instructions.

Manufacturing barriers include:

• Consistent particle-size control.
• Uniform coating of taste-masked particles.
• Prevention of segregation in multiparticulates.
• Moisture protection during granulation and storage.
• Accurate low-volume dosing.
• Compatibility between nevirapine and co-formulated active ingredients.
• Scalable production using equipment available in target regions.

Packaging is part of the excipient strategy. High-barrier blister packs, desiccant-containing bottles, unit-dose sachets, and child-resistant closures can affect stability, cost, and regulatory acceptability. For tropical markets, packaging performance may provide more practical value than a marginal improvement in dissolution.

Key Takeaways

• Nevirapine is a mature generic antiretroviral with limited compound-level exclusivity.
• Standard immediate-release tablets offer low differentiation and intense price competition.
• Pediatric taste masking, dispersible tablets, multiparticulates, and stable oral suspensions offer stronger commercial opportunities.
• Crospovidone, croscarmellose sodium, microcrystalline cellulose, mannitol, polymer coatings, suspending agents, and controlled surfactant systems are relevant excipient platforms.
• Formulation patents should claim defined compositions and measurable performance, not routine excipient combinations.
• Biosimilar risk does not apply because nevirapine is a small molecule.
• Current competitive pressure comes primarily from dolutegravir-based therapy and other modern antiretroviral regimens.
• The most defensible product concept is a low-cost, taste-masked pediatric formulation with flexible administration and high-temperature stability.

FAQs

Can nevirapine be formulated as a pediatric chewable tablet?

Yes. A chewable or orally disintegrating format is technically feasible, but bitterness, dose size, tablet friability, and rapid drug release require careful optimization. A coated-particle or resin-based taste-masking system is more likely to succeed than sweetener-only masking.

Is nevirapine suitable for a fixed-dose combination with dolutegravir?

The combination is technically possible, but the clinical and commercial rationale is limited because dolutegravir-based regimens have largely displaced nevirapine in preferred treatment pathways. Compatibility, resistance management, and guideline positioning would determine commercial viability.

Which nevirapine dosage form has the best supply-chain economics?

Dispersible tablets or sachet-based multiparticulates generally offer better transport and storage economics than ready-to-use oral suspensions. They also reduce leakage and may improve dose flexibility.

Can cyclodextrins improve nevirapine solubility?

Cyclodextrins may improve apparent solubility and reduce direct taste exposure, but their cost, dose burden, and formulation complexity can limit use in low-price antiretroviral products. They are more suitable for proof-of-concept or specialized pediatric systems than for a basic generic tablet.

Does nevirapine have an active biosimilar development market?

No. Nevirapine is a chemically synthesized small molecule. Market access is based on generic-drug pathways, bioequivalence, quality systems, and product-specific regulatory requirements rather than biosimilar approval.

References

1. World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. Geneva, Switzerland: World Health Organization.

2. U.S. Food and Drug Administration. (1996). Viramune (nevirapine) prescribing information. Silver Spring, MD: U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. Silver Spring, MD: U.S. Department of Health and Human Services.